Channel
@ribenyaoye
On this record: Topic · Growth · Engagement · Reactions · Posts · Citations · Cite this entry
39subscribers
+5 since we began measuring on 22 August 2026
Risers and fallers across the register · movement among entries of Under 1,000.
| Telegram ID | -1002619540472 |
|---|---|
| Type | Channel |
| Username | @ribenyaoye |
| Created | Between 1 March 2025 and 31 July 2025 — estimated from Telegram’s id allocation, not measured. How this range is calculated. |
| First recorded | 22 August 2026 |
| Last confirmed live | 2 October 2026 |
| Measurements held | 6 |
| Confirmed unchanged | 1 time, most recently 2 October 2026 |
| On Telegram | t.me/ribenyaoye |
Health & wellness — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-FP8, prompt version 1) read this channel’s own recent posts on 30 September 2026 and assigned it the closest of 31 fixed categories, at 88% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and why it has no browse page of its own yet.
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 2 Oct 2026, 11:00 | 39 | +3 |
| 18 Sept 2026, 08:15 | 36 | +2 |
| 10 Sept 2026, 02:19 | 34 | -1 |
| 31 Aug 2026, 04:35 | 35 | +1 |
| 23 Aug 2026, 22:05 | 34 | no change |
| 22 Aug 2026, 21:01 | 34 | first reading |
15 posts held, back to 9 May 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 1 page of Telegram’s post history, 20 posts per page.
Nothing published in the last 30 days. ERR and ER are rolling 30-day measures, so there is nothing to compute — we hold 15 posts for this entry, the most recent from 9 May 2026. An engagement rate over an empty window would be a number about nothing.
2 reactions across 2 posts, in 1 kind.
| Reaction | Count | Share | Share, drawn |
|---|---|---|---|
| ❤ | 2 | 100.0% |
No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.
Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.
Coverage. Reactions were read on 2 of the 15 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 2 reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.
Measured over the 15 most recent posts we hold, published 9 May 2026 to 9 May 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.
靶向药日本药进口药 pinned «🌹🔥日本特效【一三共止痛片】家庭常备药之一 🌹【三叉神经痛】 🌹腰间盘突出，腰椎间盘突出 🌹【腰椎管狭窄治疗剂】 🌹日本骨质疏松症特效。 🌹特效风湿 关节炎药 🌹日本•久光鎭痛贴 🌹【破腹产祛疤贴】 🌹【久光疤痕增生修复膏】 🌹【肾结石 尿路结石】 🌹【牛车肾气丸】 🌹同太和ToatlHeal【金装海狗丸】 🌹🔥新药🔥【尿频，尿失禁👀—盐酸奥昔布宁片】 🌹克里美浄顆粒 尿毒症腎衰竭肾功能不全 🌹复方痔疮口服药 🌹【便秘药 口服】 🌹🔥日本最有效的【肠炎药】🔥 🌹BM乳酸菌…»
【癌症止痛药】 帮助癌症患者减少痛苦的良药！口服：一日4次。轻度患者一次一粒，重度患者 一次2粒。每天最多不超过8粒！1，抑制各种疼痛2，在中枢神经中起作用，缓和疼痛3，用于对非中枢神经镇痛剂无法治疗的癌症疼痛和慢性疼痛。注意👇👇：于酒精，安眠药 ，镇痛剂，或其他中枢神经镇痛剂，精神药物一起服用会造成急性中毒，在口中自然融化服用!
【抗乳腺癌】 中文名：他莫昔芬 日文名：タモキシフェン 简介：日本日医工株式会社製造，针对治疗乳癌，抑制癌细胞扩散，增生，此药主要用于治疗乳腺癌的药。 药效：该抗乳腺癌药通过阻断激素受体，阳性的乳腺癌细胞与雌激素结合，破坏乳腺癌细胞的生长环境。该药用于治疗型和复发性的乳腺癌。此药主要成分是三苯氧胺-他莫昔芬。 服用方法：1天2次，1次1粒；可根据病情，适当增量，一天最高量为4粒。 注意事项：孕妇，哺乳中的女性，15岁以下儿童，备孕女性，禁止服用。
汉方【漢方补中益気湯】❤️癌症化疗后人士专用❤️癌症化疗后的身体免疫力低下，体力虚弱、精神不好、胃肠功能衰退、容易疲劳的症状:虚弱体质、疲劳倦怠、病后·术后的衰弱、食欲不振、焦躁、感冒等。癌症手术后增加抵抗能力专用！用法：一天3次，一次一包！
宫颈癌是妇科病里面的恶性肿瘤，仅次于乳腺癌，早期炎症发展到恶性的癌需要6-8年时间，一定要早预防早调理，预防炎症，推荐日本百年汉方建林松鹤堂（喜效）功效：预防子宫肌瘤病变，预防癌症，子宫内膜炎、子宫線筋証、月经障碍、痛经、卵巢囊肿、各种妇科炎症等。有助于排出子宫和卵巢内的毒素，垃圾淤血，消炎行经等！一盒一个月，三盒一疗程！
🇯🇵医院妇人科抗癌药物【依 美西坦片】28粒 （エキセメスタン錠 25mg）日本辉瑞版本药品名称 （nisamorA Tablets）规格：25mg适应症早期乳腺癌：适用于经他莫昔芬辅助治疗2-3年后，绝经后雌激素受体阳性的妇女的早期浸润性乳腺癌的辅助治疗。晚期乳腺癌：适用于经他莫昔芬治疗后病情仍有进展的自然或人工绝经后妇女的晚期乳腺癌。用法用量常规剂量:通常为每 一日次，每次25mg， 口服，饭后服用。特殊情况：根据患 者的年龄、身体状况及病情严重程度等因素，由医生进行剂量调整。
【莱博雷生】日本最新非精神类不眠治疗剂。 【莱博雷生】（Lemborexant）是一种可逆性、竞争性和口服活性的食欲素OX1和OX2受体的双重拮抗剂，可抑制食欲素神经传递，调节睡眠-觉醒节律。莱博雷生对OX2R具有更强的抑制作用，可抑制REM和非REM睡眠驱动，从而可以为患者提供更快的睡眠开始、更好的睡眠维持。该药已于2019年12月获美国FDA批准上市，这也是FDA批准的第2款双重食欲素受体拮抗剂，用于治疗成人睡眠开始和/或睡眠维持困难为特征的失眠症。随后在日本、加拿大、澳大利亚、中国香港在内的数十个国家及地区相继上市。去年，受益“港澳药械通”政策，莱博雷生已落地大湾区，在指定医药先行使用。美国上市基于两项关键3期临床研究结果显示：莱博雷生不会导致反跳性失眠，亦没有证据显示停药后会产生戒断效应，这表明服药达一年不会产生躯体依赖。安全性方面，所有的临床试验均未发现有受试者有明显的毒副作用，其主要的不良反应为昏睡。服用方法：睡前一…
甲流特效，第一天吃，第二天上班的就上班，读书的就读书，一粒见效！备一盒 因为发病24小时之内用药，效果显著，价格也不贵。
杏林最强消炎【左氧氟沙星】在感染过程中抑制细菌和其他物质DNA复制并具有杀菌作用。治疗范围：性皮肤感染、淋巴结炎、慢性脓皮症、外伤或烧伤及手术创等的二次感染、乳腺炎、喉头炎、扁桃体炎(扁桃体周围炎、扁桃体周围脓肿)、急性支气管炎、肺炎、慢性呼吸道病变的二次感染、膀胱炎、肾盂肾炎、前列腺炎、睾丸炎、尿道炎、妇科炎症、胆囊炎、中耳炎、鼻腔炎、牙周组织炎、感冒引发的炎症。用法用量：1日1次，1次500mg。根据病症急行期可以调整到一日1000mg。
🔥明治GABA睡眠丸 120粒 加强版蓝色 草本复合深度睡眠片一個月量，含降高血压成分，缓和工作疲累带来的精神紧张，不含褪黑素，核心释压成分，食品级GABA成分，生物发酵法提取，温和无依赖，让睡眠开始有深度，卸下焦虑烦恼 安睡一整晚。 每天2粒，释放压力情绪，重建睡眠生物钟，安睡整晚，睡醒精力充沛✅精神饱满一整天✅ 入睡难，睡眠浅❌倒时差，睡醒累❌心情差，爱做梦❌1瓶1个月量，30天养成睡眠好习惯！
❤1
【抗眩晕失衡剂】中文名：盐酸地芬尼多,敌芬尼朵。防治多种原因引起的眩晕、恶心、呕吐。防治眩晕症、缓解晕动病、减轻手术麻醉后不适、改善脑血管疾病症状.缓解耳水不平衡、梅尼埃病、前庭神经元炎等疾病引发的眩晕症状.乘坐车、船、飞机 预防和减轻头晕、恶心、呕吐等 症状，保障出行舒适度。脑动脉硬化症、缺血性脑血管病患者，盐酸地芬尼多片可增加脑部血流量，改善脑部血液循环，缓解因脑部供血不足引起的头晕、站立不稳等症状。 服用方法：一天3次，一次1-2粒。
加班熬夜操劳过度必备品【大正有机护体剂】牛磺酸有机物 改善心肌缺血 心脏机能衰退 防止脑卒死 防止猝死 促进代谢与能量生成 稳定脑细胞膜电位 缓解神经兴奋性过度，对焦虑改善作用 保护细胞免受炎症因子侵害 对肝脏、视网膜等器官有保护作用。服用方法：1天2-3次 1次1包。
Showing the 12 most recent of 15 posts we hold for @ribenyaoye. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Named by 1 registered channel — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.
Named by
Channels on the register whose posts name this channel's handle.
A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 2 October 2026 — this entry's latest reading, not the date you are reading this.
“靶向药日本药进口药” (@ribenyaoye), 39 subscribers as measured 2 October 2026. Telegram Register, tgregister.com/channel/ribenyaoye.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.